[Breaking] SK Biopharmaceuticals Posts Q3 2026 Operating Profit of KRW 116.2 Billion, Up 65.9% Year-on-Year
SK Biopharmaceuticals has provisionally recorded consolidated operating profit of KRW 116.283 billion for the third quarter of 2026, up 65.9% from the same period last year. According to a regulatory filing on the 5th, SK Biopharmaceuticals' Q3 2026 consolidated revenue came to KRW 258.418 billion,
![[Breaking] SK Biopharmaceuticals Posts Q3 2026 Operating Profit of KRW 116.2 Billion, Up 65.9% Year-on-Year](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581911%2Fa630da1c47d6049c%2Foriginal.webp&w=1920&q=75)
SK Biopharmaceuticals has provisionally recorded consolidated operating profit of KRW 116.283 billion for the third quarter of 2026, up 65.9% from the same period last year.
According to a regulatory filing on the 5th, SK Biopharmaceuticals' Q3 2026 consolidated revenue came to KRW 258.418 billion, up 34.8% year-on-year and 4.5% higher than the previous quarter's revenue of KRW 247.367 billion.
Operating profit of KRW 116.283 billion rose 65.9% from KRW 70.106 billion a year earlier and 19.8% from KRW 97.064 billion in the previous quarter. Profit from continuing operations before income tax expense amounted to KRW 95.37 billion, up 53.5% year-on-year and 2.2% from the previous quarter.
In contrast, net income for the period fell 23.9% year-on-year and 36.1% quarter-on-quarter to KRW 54.341 billion. Net profit attributable to owners of the parent company also declined 26.7% year-on-year to KRW 54.341 billion.
■ Cumulative Operating Profit for Q1–Q3 Up 92.3%
Cumulative revenue for the first three quarters of this year totaled KRW 733.671 billion, up 43.2% from the same period last year. Cumulative operating profit rose 92.3% to KRW 303.115 billion.
Cumulative profit from continuing operations before income tax expense increased 146.5% year-on-year to KRW 288.708 billion, while cumulative net income for the period grew 100.9% to KRW 242.14 billion. Cumulative net profit attributable to owners of the parent company climbed 87.6% year-on-year to KRW 244.568 billion.
■ Earnings Conference Call at 10:30 a.m.
SK Biopharmaceuticals announced that it will hold a conference call at 10:30 a.m. today to present its Q3 2026 business results to investors and analysts. Presentation materials will be posted on the company's website.
Meanwhile, these figures are provisional consolidated results prepared in accordance with Korean International Financial Reporting Standards (K-IFRS). The company noted that the external auditor's review of the period's results has not yet been completed, and the figures may be subject to change during the review process.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.

![[Breaking] Nvidia Falls 3% While AMD Rises 5% and Broadcom 4%... Mixed Fortunes for Semiconductor Stocks on NYSE](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F623360%2Fc7c94797e342c86e%2Fvariants%2Fhero.webp&w=1920&q=75)

![Evernorth Holdings Plunges 14%... New York Stock Market on Edge Amid Nvidia Woes and Midterm Election Aftermath [Breaking]](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F10%2F614266%2F7b8d225fe874b712%2Fvariants%2Fhero.webp&w=1920&q=75)